Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor‐mutated non‐small‐cell lung cancer: A narrative review

Here, we review the molecular mechanism and pharmacokinetics of flavonoids in treatment resistant EGF receptor (EGFR)‐mutated non‐small‐cell lung cancer (NSCLC) particularly possible mechanism(s) delicaflavone, a biflavonoid extracted from S elaginella doederleinii Hieron . EGFR TK inhibitors (EGFR‐TKI) are ubiquitously used NSCLC bearing mutations. However, patients treated with EGFR‐TKI inevitably continuously develop resistance. In laboratory studies, flavonoids, as potential adjuvants for chemotherapy, exhibited anti‐cancer properties such inhibition chemoresistance by interference ABC transporters‐induced drug efflux, curbing c‐MET amplification, or reversal T790M mutation‐mediated The current aims at summarizing association between potentials their regulatory roles certain types mutation that could trigger resistance NSCLC. Potential practical applications these phytochemicals, well relevant pharmacokinetics, also discussed.